XIAP、survivin、LPA及CA125在上皮性卵巢癌中的表达

山东大学学报(医学版)

XIAP、survivin、LPA及CA125在上皮性卵巢癌中的表达

张意茗,张向宁

山东大学齐鲁医院妇产科，山东济南 250012

收稿日期:2007-01-15 修回日期:1900-01-01 出版日期:2007-03-24 发布日期:2007-03-24
通讯作者: 张向宁

Expression of XIAP, Survivin, LPA and CA125 in human epithelial ovarian carcinoma

ZHANG Yi-ming, ZHANG Xiang-ning

Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University，Jinan 250012, Shandong, China

Received:2007-01-15 Revised:1900-01-01 Online:2007-03-24 Published:2007-03-24
Contact: ZHANG Xiang-ning

摘要/Abstract

摘要： 目的：探讨上皮性卵巢癌患者的组织标本中survivin mRNA和XIAP mRNA及血浆LPA和血清CA125表达与卵巢癌患者临床病理学指标的关系。方法：采用逆转录－聚合酶链反应(RT-PCR)法分别检测50例上皮性卵巢癌及12例正常卵巢组织标本中survivin mRNA和XIAP mRNA的表达，检测50例卵巢癌、44例卵巢良性疾病患者及20例健康女性血浆LPA和血清CA125的表达情况。结果：在正常卵巢标本与卵巢癌标本中，XIAP mRNA的阳性表达率分别为2/12（16.7%）、37/50（74%），差异有统计学意义（P<0.05）；survivin mRNA的阳性表达率分别为0、42/50（84%），差异有统计学意义（P<0.05）。survivin mRNA与XIAP mRNA在卵巢癌组织中的表达呈正相关rs=0.03(P<0.05)。XIAP、survivin表达与肿瘤的病理分期、病理类型、淋巴结转移和腹水形成有关（P<0.05）。卵巢癌组血浆LPA均值为(7.67±3.02)μmol/L，阳性率为78.0%；卵巢良性疾病组LPA均值为(2.734±1.471)μmol/L，阳性率为27.3%，健康对照组LPA均值为(1.557±1.294)μmol/L，阳性率为5.0%，三者间的差异有统计学意义（P<0.05）。卵巢癌的诊断中LPA的特异度为75.0%，高于CA125；早期卵巢癌的诊断中二者联合检测的灵敏度最高，为85.7%；LPA的灵敏度为71.4%，高于CA125的28.6%，差异有统计学意义（P<0.05）。Ⅱ～Ⅳ期患者血浆LPA水平较Ⅰ期显著升（P<0.01）；Ⅱ～Ⅳ期各期之间无显著性差异（P>0.05）。3种病理类型中LPA阳性率的差异无显著性（P>0.05）。结论: survivin和XIAP基因系重要的肿瘤相关基因，与卵巢癌的发生发展有关；血浆LPA诊断早期卵巢癌的特异性和敏感性均高于CA125，联合检测有较高的临床价值。

Abstract: Objective: To explore the expression of Survivin mRNA and XIAP mRNA in ovarian tissues and LPA and serum CA125 in plasma of patients with epithelial ovarian carcinoma and evaluate their correlation with the clinicopathological and other molecular parameters. Methods: The expression of Survivin mRNA and XIAP mRNA was determined by RT-PCR in 50 epithelial ovarian carcinoma tissues and 12 normal ovarian tissues， and the level of plasma LPA was determined by a reagent in 50 patients with epithelial ovarian carcinoma, 44 with ovarian benign diseases and 20 healthy women． Results: Expression of Survivin mRNA and XIAP mRNA had significant differences between epithelial ovarian carcinoma and normal ovarian tissues (P<0.05). Expression of Survivin mRNA and XIAP mRNA increased in the 50 epithelial ovarian carcinoma tissues, which were related to the clinicopathological stage, degree, and lymph node metastasis (P<0.05). Expression of survivin mRNA correlated with that of XIAP mRNA in 50 epithelial ovarian carcinoma tissues rs=0.03(P＜0.05). In the group of ovarian carcinoma, the mean LPA in plasma was(7.67±3.02)μmol/L and the positive rate was 78.0%, while in the group of ovarian benign diseases, they were(2.734±1.471)μmol/L and 27.3%, respectively，　in the group of healthy women, they were(1.557±1.294)μmol/L and 5%, respectively. The LPA specificity was 75.0%，which was higher than CA125-s. The sensitivity of LPA was 71.4%，which was higher than that of CA125 (28.6%)（P<0.05）. The level of LPA in stageⅡ-Ⅳ was significantly higher than that in stageⅠ (P<0.05). There were no statistical significance among stagesⅡ-Ⅳ（P>0.05）, and no significant relations between the LPA value and the pathologic types（P>0.05）. Conclusions: Survivin and XIAP are candidate tumor genes related to the development of ovarian carcinoma. In early diagnosis of ovarian carcinoma, the specificity and sensitivity of LPA are both higher than those of CA125.

Key words: Ovarian neoplasms, Genes, X-linked inhibitor of apoptosis protein, Genes, Survivin, Reverse Transcriptase-Polymerase Chain Reaction, Lysophosphatidic acid

中图分类号:

R737.31

张意茗,张向宁. XIAP、survivin、LPA及CA125在上皮性卵巢癌中的表达[J]. 山东大学学报(医学版), 2007, 45(3): 317-321.

ZHANG Yi-ming,ZHANG Xiang-ning. Expression of XIAP, Survivin, LPA and CA125 in human epithelial ovarian carcinoma[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 317-321.

参考文献

相关文章 15

[1]	王谋龙,陈永坤,邢德广,曲良锁,王成伟. 经颅多普勒超声早期预测动脉瘤夹闭术后迟发性脑缺血的临床分析[J]. 山东大学学报（医学版）, 2017, 55(11): 38-41.
[2]	陆衡,刘延国,李曙光,陈晓康,田琦,衣翠华,王秀问. YKL-40对卵巢癌SKOV-3细胞迁移能力的影响[J]. 山东大学学报（医学版）, 2017, 55(1): 33-38.
[3]	赵路,矫俊,张腾,焦薪霖,崔保霞. 肝X受体在卵巢癌组织中的表达及T0901317在卵巢癌细胞系SKOV3中的作用[J]. 山东大学学报（医学版）, 2017, 55(1): 49-53.
[4]	赵云霞,宋静,张灿灿,林雪艳,尉蔚,田永杰. CXXC4增强上皮性卵巢癌细胞对化疗药物的敏感性[J]. 山东大学学报（医学版）, 2016, 54(3): 24-29.
[5]	徐志宏,吴小华,姚铁柱,王晓翔,段晓阳,史健. mir-99a的表达与上皮性卵巢癌患者预后的关系[J]. 山东大学学报（医学版）, 2016, 54(3): 77-80.
[6]	张春霞,邹存华,宋冬冬,余江. P38MAPK信号通路对卵巢癌中尿激酶型纤维蛋白酶原激活剂的影响[J]. 山东大学学报（医学版）, 2016, 54(2): 68-74.
[7]	吕树卿, 尉蔚, 张灿灿, 田永杰. HGF/PARP-1信号通路调控卵巢癌细胞侵袭转移的作用[J]. 山东大学学报（医学版）, 2015, 53(7): 1-7.
[8]	付伟1，高文娟2，张志勉1，曲迅2，赵玉霞3. 罗勒多糖对卵巢癌SKOV3细胞VEGF受体表达的调控作用及对其侵袭能力的影响[J]. 山东大学学报（医学版）, 2014, 52(5): 39-43.
[9]	李燕，尉蔚，吕树卿，田永杰. PARP-1对卵巢癌血管生成的影响[J]. 山东大学学报（医学版）, 2014, 52(4): 97-101.
[10]	贾宗洋,张向宁,靳艳慧,魏美玲. PD98059联合顺铂对卵巢癌细胞增殖的影响[J]. 山东大学学报(医学版), 2013, 51(2): 27-32.
[11]	丁佰娟，张友忠，吕昌帅，姜侃，刘洪丽. TMPyP4-PDT对人宫颈癌细胞的杀伤效应[J]. 山东大学学报(医学版), 2012, 50(11): 53-57.
[12]	张敬敬1，王哲1，田永杰1，张捷2. PJ34对卵巢癌C13*细胞生长活性及耐药性的影响[J]. 山东大学学报(医学版), 2012, 50(1): 46-50.
[13]	刘敏1,2，王莉2，周婷2，荣风年2. PR/AR基因多态性与上皮性卵巢癌易感性的研究[J]. 山东大学学报(医学版), 2011, 49(9): 144-148.
[14]	康马飞，卜庆，刘瑛，骆梅青，廖漓漓，涂江江. 培美曲塞单药或联合奈达铂治疗对卡铂及紫杉醇耐药的复发晚期上皮性卵巢癌[J]. 山东大学学报(医学版), 2011, 49(5): 122-124.
[15]	阚艳艳1，张敬敬1，王哲1，田永杰1，戚晓霞2，张捷3. RNA干扰抑制PARP-1基因表达对卵巢癌细胞增殖及耐药性的影响[J]. 山东大学学报(医学版), 2011, 49(4): 52-56.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed